Based on our 2009 Pharmacor Breast Cancer report, Decision Resources is offering an exclusive Pharmacor analyst call entitled Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin? Because this analyst call features report findings, it is ONLY available to purchasers of this report.

 

This analyst call was held on December 9, 2009. Contact us to learn how you can purchase this report and access a recorded playback of this event.

Click here to view the invite.